TSXV:GENE

Stock Analysis Report

Executive Summary

Invictus MD Strategies Corp. and its subsidiaries primarily engage in the investment, acquisition, and development of synergistic businesses in the medical cannabis industry in Canada.

Snowflake

Fundamentals

Imperfect balance sheet and overvalued.

Share Price & News

How has Invictus MD Strategies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.1%

GENE

2.6%

CA Pharmaceuticals

-0.2%

CA Market


1 Year Return

-87.3%

GENE

-50.2%

CA Pharmaceuticals

1.5%

CA Market

Return vs Industry: GENE underperformed the Canadian Pharmaceuticals industry which returned -50.2% over the past year.

Return vs Market: GENE underperformed the Canadian Market which returned 1.5% over the past year.


Shareholder returns

GENEIndustryMarket
7 Day-3.1%2.6%-0.2%
30 Day-34.0%-20.3%-3.5%
90 Day-53.7%-32.5%-1.8%
1 Year-87.3%-87.3%-50.2%-50.2%5.1%1.5%
3 Year-83.2%-83.2%78.2%76.8%13.3%3.2%
5 Yearn/a285.7%285.7%25.2%7.2%

Price Volatility Vs. Market

How volatile is Invictus MD Strategies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Invictus MD Strategies undervalued compared to its fair value and its price relative to the market?

0.19x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GENE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GENE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GENE is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: GENE is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GENE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GENE is good value based on its PB Ratio (0.2x) compared to the CA Pharmaceuticals industry average (1.9x).


Next Steps

Future Growth

How is Invictus MD Strategies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

86.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Invictus MD Strategies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Invictus MD Strategies performed over the past 5 years?

-64.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: GENE is unprofitable, and losses have increased over the past 5 years at a rate of -64.9% per year.

Accelerating Growth: Unable to compare GENE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GENE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).


Return on Equity

High ROE: GENE has a negative Return on Equity (-36.2%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: GENE is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: GENE is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Invictus MD Strategies's financial position?


Financial Position Analysis

Short Term Liabilities: GENE's short term assets (CA$15.1M) exceeds its short term liabilities (CA$7.9M)

Long Term Liabilities: GENE's short term assets (15.1M) do not cover its long term liabilities (21.1M)


Debt to Equity History and Analysis

Debt Level: GENE's debt to equity ratio (13.9%) is considered satisfactory

Reducing Debt: Insufficient data to determine if GENE's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: GENE has a high level of physical assets or inventory.

Debt Coverage by Assets: GENE's debt is covered by short term assets (assets are 1.063490x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GENE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: GENE has less than a year of cash runway if free cash flow continues to reduce at historical rates of -83.6% each year


Next Steps

Dividend

What is Invictus MD Strategies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate GENE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GENE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if GENE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GENE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GENE's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Invictus MD Strategies's salary, the management and board of directors tenure and is there insider trading?

1.6yrs

Average management tenure


CEO

Marc Ripa 0

0yrs

Tenure

0

Mr. Marc Ripa serves as Interim Chief Executive Officer at Invictus MD Strategies Corp. since October 8, 2019. Mr. Ripa is the Chief Operating Officer of Invictus MD Strategies Corp. since June 5, 2019. Mr ...


Management Age and Tenure

1.6yrs

Average Tenure

Experienced Management: GENE's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Age and Tenure

0.8yrs

Average Tenure

55yo

Average Age

Experienced Board: GENE's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: GENE insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$11,04019 Aug 19
Colin Kinsley
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares30,000
Max PriceCA$0.37
BuyCA$500,00009 Jul 19
Trevor Dixon
EntityIndividual
Role
Member of the Board of Directors
President & Director
Shares1,250,000
Max PriceCA$0.40
SellCA$12,20023 Jan 19
Aaron Bowden
EntityIndividual
Role
Senior Key Executive
Shares10,000
Max PriceCA$1.22
BuyCA$32,13018 Nov 18
Brenda Dixon
EntityIndividual
Role
Alternate Director
Chief Science Officer & Alternate Director
Shares25,500
Max PriceCA$1.26
BuyCA$8,88031 Oct 18
Brenda Dixon
EntityIndividual
Role
Alternate Director
Chief Science Officer & Alternate Director
Shares7,400
Max PriceCA$1.20
BuyCA$76,73630 Oct 18
Brenda Dixon
EntityIndividual
Role
Alternate Director
Chief Science Officer & Alternate Director
Shares57,000
Max PriceCA$1.38
BuyCA$88,92624 Oct 18
Brenda Dixon
EntityIndividual
Role
Alternate Director
Chief Science Officer & Alternate Director
Shares71,000
Max PriceCA$1.28

Ownership Breakdown


Management Team

  • Gene Simmons (69yo)

    Chief Evangelist Officer

    • Tenure: 1.6yrs
  • Larry Heinzlmeir

    Vice President of Marketing & Communications

    • Tenure: 2.8yrs
  • Dan Kriznic (40yo)

    Founder and Advisor to Chairman & CEO

    • Tenure: 5.3yrs
    • Compensation: CA$1.09m
  • Aaron Bowden

    • Tenure: 0.3yrs
    • Compensation: CA$30.00k
  • Trevor Dixon

    President & Director

    • Tenure: 0.4yrs
    • Compensation: CA$240.00k
  • Brenda Dixon

    Chief Science Officer & Alternate Director

    • Tenure: 0yrs
  • Kathy Love

    Corporate Secretary

    • Tenure: 0yrs
  • Harbir Toor

    Chief Financial Officer

    • Tenure: 0.6yrs
  • Marc Ripa

    COO & Interim CEO

    • Tenure: 0yrs

Board Members

  • Keith Stein (55yo)

    Independent Director

    • Tenure: 0.8yrs
  • Paul Sparkes (55yo)

    Independent Chairman

    • Tenure: 0.9yrs
    • Compensation: CA$22.50k
  • Rick Lee (63yo)

    Independent Director

    • Tenure: 0.3yrs
  • Milun Tesovic

    Member of Advisory Board

    • Tenure: 4.5yrs
  • Dario Meli (44yo)

    Member of Advisory Board

    • Tenure: 4.6yrs
  • Colin Kinsley

    Independent Director

    • Tenure: 0.3yrs
  • Trevor Dixon

    President & Director

    • Tenure: 0.4yrs
    • Compensation: CA$240.00k
  • Brenda Dixon

    Chief Science Officer & Alternate Director

    • Tenure: 0yrs

Company Information

Invictus MD Strategies Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Invictus MD Strategies Corp.
  • Ticker: GENE
  • Exchange: TSXV
  • Founded: 2014
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$19.310m
  • Shares outstanding: 124.58m
  • Website: https://www.invictus-md.com

Location

  • Invictus MD Strategies Corp.
  • 15047 Marine Drive
  • Suite 300
  • White Rock
  • British Columbia
  • V4B 1C5
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
8IS2DB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2015
IVIT.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 2015
GENETSXV (TSX Venture Exchange)YesCommon SharesCACADJan 2015

Biography

Invictus MD Strategies Corp. and its subsidiaries primarily engage in the investment, acquisition, and development of synergistic businesses in the medical cannabis industry in Canada. It produces and sell ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 00:48
End of Day Share Price2019/10/18 00:00
Earnings2019/07/31
Annual Earnings2019/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.